Skip to content

Study · Non-randomized trial · n = 35 · 2007

5 results

The effects of GnRH antagonist on the endometrium of normally menstruating women.

Sirayapiwat P, Suwajanakorn S, Triratanachat S, Niruthisard S

Journal of assisted reproduction and genetics30 Nov 2007Cited by 7 (Europe PMC)

PMID18049889 (opens in a new tab)PMCIDPMC3455003 (opens in a new tab)DOI10.1007/s10815-007-9184-z (opens in a new tab)PepBankPUB-18049889
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In regularly menstruating women, endometrial histological dating did not differ between ganirelix-treated and control cycles.

    In plain wordsIn regularly menstruating women, endometrial histological dating did not differ between ganirelix-treated and control cycles.

    Peptide
    Ganirelix
    Outcome
    No significant changeEndometrial histological dating
    Study

    n = 35

    Comparator
    control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/d · 3 daysAs given in this study (human).

    Source sentences

    Summary
    No statistical differences between histological dating and the endometrial thickness in the control and GnRH antagonist-treated cycles.
    3 context sentences
    Summary · context
    Prospective, self-controlled study.
    Summary · context
    The thirty-five volunteers were studied for two cycles: one as a control and the other, GnRH antagonist-treated cycles in which ganirelix 0.25 mg/d was given daily for 3 days, starting when the largest follicle reached 15 mm.
    Summary · context
    Endometrial biopsy was performed on day 6 after ovulation for histological dating and morphometric study.
  2. 02HumanNon-randomized trialEfficacy outcome

    In regularly menstruating women, endometrial thickness did not differ between ganirelix-treated and control cycles.

    In plain wordsIn regularly menstruating women, endometrial thickness did not differ between ganirelix-treated and control cycles.

    Peptide
    Ganirelix
    Outcome
    No significant changeEndometrial thickness
    Study

    n = 35

    Comparator
    control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/d · 3 daysAs given in this study (human).

    Source sentences

    Summary
    No statistical differences between histological dating and the endometrial thickness in the control and GnRH antagonist-treated cycles.
    3 context sentences
    Summary · context
    Prospective, self-controlled study.
    Summary · context
    The thirty-five volunteers were studied for two cycles: one as a control and the other, GnRH antagonist-treated cycles in which ganirelix 0.25 mg/d was given daily for 3 days, starting when the largest follicle reached 15 mm.
    Summary · context
    Endometrial biopsy was performed on day 6 after ovulation for histological dating and morphometric study.
  3. 03HumanNon-randomized trialEfficacy outcome

    In regularly menstruating women, morphometric parameters did not differ between ganirelix-treated and control cycles.

    In plain wordsIn regularly menstruating women, endometrial morphometric parameters did not differ between ganirelix-treated and control cycles.

    Peptide
    Ganirelix
    Outcome
    No significant changeEndometrial morphometric parameters
    Study

    n = 35

    Comparator
    control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/d · 3 daysAs given in this study (human).

    Source sentences

    Summary
    All morphometric parameters were also not different.
    3 context sentences
    Summary · context
    Prospective, self-controlled study.
    Summary · context
    The thirty-five volunteers were studied for two cycles: one as a control and the other, GnRH antagonist-treated cycles in which ganirelix 0.25 mg/d was given daily for 3 days, starting when the largest follicle reached 15 mm.
    Summary · context
    Endometrial biopsy was performed on day 6 after ovulation for histological dating and morphometric study.
  4. 04HumanNon-randomized trialEfficacy outcome

    In regularly menstruating women, serum estradiol was significantly lower in ganirelix-treated cycles than control cycles.

    In plain wordsIn regularly menstruating women, serum estradiol was lower in ganirelix-treated cycles than control cycles.

    Peptide
    Ganirelix
    Outcome
    DecreaseSerum estradiol
    Study

    n = 35

    Comparator
    control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/d · 3 daysAs given in this study (human).

    Source sentences

    Summary
    Serum estradiol and LH levels were significantly lower in GnRH antagonist-treated cycles.
    3 context sentences
    Summary · context
    Prospective, self-controlled study.
    Summary · context
    The thirty-five volunteers were studied for two cycles: one as a control and the other, GnRH antagonist-treated cycles in which ganirelix 0.25 mg/d was given daily for 3 days, starting when the largest follicle reached 15 mm.
    Summary · context
    Endometrial biopsy was performed on day 6 after ovulation for histological dating and morphometric study.
  5. 05HumanNon-randomized trialEfficacy outcome

    In regularly menstruating women, serum LH was significantly lower in ganirelix-treated cycles than control cycles.

    In plain wordsIn regularly menstruating women, serum LH was lower in ganirelix-treated cycles than control cycles.

    Peptide
    Ganirelix
    Outcome
    DecreaseSerum LH
    Study

    n = 35

    Comparator
    control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/d · 3 daysAs given in this study (human).

    Source sentences

    Summary
    Serum estradiol and LH levels were significantly lower in GnRH antagonist-treated cycles.
    3 context sentences
    Summary · context
    Prospective, self-controlled study.
    Summary · context
    The thirty-five volunteers were studied for two cycles: one as a control and the other, GnRH antagonist-treated cycles in which ganirelix 0.25 mg/d was given daily for 3 days, starting when the largest follicle reached 15 mm.
    Summary · context
    Endometrial biopsy was performed on day 6 after ovulation for histological dating and morphometric study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.